Trials: Prophylaxis of A/H3N2v Influenza

Phase 2 N=304 2017 A/H7N9 IIV Revaccination

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMT) of Serum Hemagglutination Inhibition (HAI) Antibodies on Day 22 Against the 2017 Influenza A/H7N9 Vaccine Virus — 22.7; 116.1; 77.7; 190.3…

National Institute of Allergy and Infectious… Results Jul 2021 0.7% serious AE View details

Phase 2 N=30 H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Avian Influenza · H1N1 Influenza · Influenza

Primary: Percentage of Participants Achieving Seroconversion Based on HAI Titer (A/H7N9 Vaccine, With and Without Adjuvant) — 80.0; 0 percentage of participants

National Institute of Allergy and Infectious… Results Jan 2022 3.3% serious AE View details

Phase 1 N=60 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)

Influenza, Human

Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants

Institute of Vaccines and Medical Biologicals… Results Jan 2019 0.0% serious AE View details

Phase 2 N=145 Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Influenza

Primary: Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR — 649.7; 726.1; 646.5; 726.1 hour*Log10 Viral Particles/ ml — p=0.1711

Barinthus Biotherapeutics Results Mar 2021 0.8% serious AE View details

Phase 1 N=43 H3N2 M2SR in Pediatric Population

Influenza · Influenza Immunisation

Primary: Number of Participants With Adverse Events of Special Interest (AESIs) — 0; 0 Participants

National Institute of Allergy and Infectious… Results Oct 2021 0.0% serious AE View details

Phase 2 N=153 Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model

Influenza

Primary: Number of Participants With Mild to Moderate Influenza Disease (MMID) — 23; 13; 15; 19 Participants — p=0.03

PepTcell Limited Results May 2019 0.0% serious AE View details

Phase 3 N=64 Zanamivir Versus Trivalent Split Virus Influenza Vaccine

Influenza

Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25

Mount Sinai Hospital, Canada Results Sep 2011 5.0% serious AE View details

Phase 3 N=889 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3

Influenza, Human

Primary: Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE) — 1; 0; 1; 0 Participants

Institute of Vaccines and Medical Biologicals… Results Jul 2019 0.7% serious AE View details

Phase 4 N=300 Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

Influenza · Healthy

Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0; 0.4 Percentage of Participant

MedImmune LLC Results Nov 2016 0.3% serious AE View details

Phase 2 N=372 Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMT) of Serum Hemagglutinin Inhibition (HAI) Antibodies — 23.3; 19.9; 24.2; 6.0 titer

National Institute of Allergy and Infectious… Results May 2021 3.2% serious AE View details

Phase 4 N=300 Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Influenza · Healthy

Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0.4; 0.0 percentage of participants

MedImmune LLC Results Nov 2014 1.0% serious AE View details

Phase 3 N=10,160 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases

Primary: Number of Occurrences of Protocol-Defined Respiratory Illness Caused by Vaccine-Matched Influenza Strains — 110; 169 Number of cases

Medicago Results Aug 2023 1.1% serious AE View details

Phase 4 N=303 A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Influenza

Primary: Percentage of Participants Reporting Fever Within 7 Days Post Vaccination — 0.0; 1.7 Percentage of Participants

MedImmune LLC Results Feb 2014 0.7% serious AE View details

Phase 1 N=48 Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine

Influenza

Primary: Number of Participants With Maximum Systemic Reaction After Vaccination 1 — 16; 15; 9; 6 Participants

PATH Results Feb 2019 2.1% serious AE View details

Phase 3 N=12,794 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases

Primary: Number of Occurrences of Protocol-Defined Influenza-Like Illness (ILI) Due to Any Laboratory-Confirmed Influenza Strains — 118; 130 Number of cases

Medicago Results Jun 2023 4.2% serious AE View details

Phase 4 N=301 Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season

Influenza · Healthy

Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 1.7; 0.4 Percentage of participants

MedImmune LLC Results Oct 2017 0.0% serious AE View details

Phase 2 N=149 Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Avian Influenza · Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Against the 2017 H7N9 Inactivated Influenza Vaccine (IIV) Strain After Second H7N9…

National Institute of Allergy and Infectious… Results Aug 2020 0.7% serious AE View details

Phase 2 N=180 2013/2017 H7N9 Prime-Boost Interval

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutinin Inhibition (HAI) Antibodies Against the Influenza A/H7N9 Study Vaccine Viruses on Day 43 in Participants Who Received…

National Institute of Allergy and Infectious… Results Aug 2021 2.2% serious AE View details

Phase 4 N=22 Special Access Program IMVAMUNE®

Vaccination

Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects

Bavarian Nordic Results Aug 2020 0.0% serious AE View details

Phase 1 N=38 Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine

Influenza

Primary: Percentage of Participants With Immediate Reactions — 0; 0; 28; 10 Participants

PATH Results Feb 2019 0.0% serious AE View details

Phase 3 N=120 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season

Influenza

Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…

Abbott Results Dec 2016 0.0% serious AE View details

Phase 4 N=300 Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season

Influenza · Healthy

Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0; 0 Percentage of Participants

MedImmune LLC Results Jan 2019 0.3% serious AE View details

Phase 4 N=402 A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Influenza, Human

Primary: The Frequency and Intensity of Fever Events Occurring During the 7 Days After Each Administration of CSL TIV Vaccine. — 8.2; 4.1; 2.1; 2.1 Percentage of subjects

Seqirus Results Oct 2015 0.3% serious AE View details

Phase 1 N=206 Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Influenza A

Primary: Number of Participants With Local and Systemic Adverse Events (AEs) Through 29 Days Post-vaccination With Bris10 M2SR and Cumulatively Through Day 209 — 28; 24…

FluGen Inc Results Mar 2022 0.5% serious AE View details

Phase 1 N=60 Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

Influenza

Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants

National Institute of Allergy and Infectious… Results Nov 2023 0.0% serious AE View details

Phase 3 N=1,202 Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults

Virus Diseases · RNA Virus Infections · Respiratory Tract Infections

Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain — 603.7; 595.6; 630.6; 96.3 titers

Medicago Results Aug 2023 0.1% serious AE View details

Phase 3 N=7,250 Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

Influenza

Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…

Alachua Government Services, Inc. Results Nov 2025 0.8% serious AE View details

Phase 2 N=209 Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

Influenza

Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain on Day 0 — 87.5704; 71.2385; 69.1840; 60.7941…

Medicago Results Jul 2023 8.6% serious AE View details

Phase 2 N=179 A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Influenza

Primary: Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza Virus — 17; 19; 15…

Vaxart Results Oct 2022 0.0% serious AE View details

Phase 4 N=125 Development of Childhood Anti-Influenza Immunity

Influenza · Influenza Immunisation

Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage

National Institute of Allergy and Infectious… Results Mar 2022 View details

Clinical Trial Search

Phase 2 N=304 2017 A/H7N9 IIV Revaccination

Phase 2 N=30 H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Phase 1 N=60 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)

Phase 2 N=145 Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Phase 1 N=43 H3N2 M2SR in Pediatric Population

Phase 2 N=153 Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model

Phase 3 N=64 Zanamivir Versus Trivalent Split Virus Influenza Vaccine

Phase 3 N=889 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3

Phase 4 N=300 Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

Phase 2 N=372 Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Phase 4 N=300 Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Phase 3 N=10,160 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Phase 4 N=303 A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Phase 1 N=48 Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine

Phase 3 N=12,794 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Phase 4 N=301 Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season

Phase 2 N=149 Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Phase 2 N=180 2013/2017 H7N9 Prime-Boost Interval

Phase 4 N=22 Special Access Program IMVAMUNE®

Phase 1 N=38 Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine

Phase 3 N=120 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season

Phase 4 N=300 Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season

Phase 4 N=402 A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Phase 1 N=206 Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Phase 1 N=60 Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

Phase 3 N=1,202 Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults

Phase 3 N=7,250 Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

Phase 2 N=209 Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

Phase 2 N=179 A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Phase 4 N=125 Development of Childhood Anti-Influenza Immunity